晚期滤泡性淋巴瘤患者接受R-CHOP治疗:JCOG0203研究超过15年随访
JCOG0203随机临床试验对248例晚期滤泡性淋巴瘤患者进行长期分析,比较每2周或3周R-CHOP方案(6周期,无利妥昔单抗维持)的远期结局。中位随访15.9年,15年总生存率为76.2%,非血液学和血液学第二肿瘤15年累积发生率分别为12.8%和3.7%,组织学转化中位时间8年。R-CHOP在延长随访中维持安全性和疗效,是晚期滤泡性淋巴瘤可行的首选方案。
要点
- 中位随访15.9年,15年总生存率为76.2%。
- 15年非血液学第二肿瘤累积发生率为12.8%,血液学第二肿瘤为3.7%。
- 组织学转化中位时间为8年。
核心结论
- R-CHOP在晚期滤泡性淋巴瘤患者中经过长期随访维持安全性和疗效,是可行的首选方案。
研究设计与样本
- 随机临床试验长期分析,纳入248例晚期滤泡性淋巴瘤患者,分配至两个治疗臂。
- R-CHOP方案每2周或3周给药,共6周期,未进行利妥昔单抗维持治疗。
- 入组完成后15年进行预设评估,中位随访15.9年。
主要发现
- 15年总生存率为76.2%。
- 无方案治疗相关死亡,也无因后续淋巴瘤治疗导致的致命性感染。
- 15年非血液学恶性肿瘤累积发生率为12.8%,血液学恶性肿瘤为3.7%。
- 组织学转化中位时间为8年。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-CD20 antibody in combination with chemotherapy extends overall survival (OS) in untreated advanced-stage follicular lymphoma (FL), yet the optimal associated therapy is unclear. Data on the cumulative incidence of secondary malignancies postrelapse after conventional immunochemotherapy are scarce. A long-term analysis of rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) as first-line treatment was conducted in a randomised clinical trial. A six-cycle R-CHOP regimen was administered every 2 or 3 weeks without rituximab maintenance. A prespecified evaluation was conducted 15 years after the completion of enrolment, following initial analysis results that showed no significant differences in outcomes at the 3-year mark. In-depth analyses were performed on the cohort of 248 patients with FL who were allocated to the two treatment arms. With a median follow-up period of 15.9 years, the 15-year OS was 76.2%. There were no protocol treatment-related deaths, nor were there any fatal infections attributable to subsequent lymphoma treatment. At 15 years, the cumulative incidence of non-haematological and haematological malignancies was 12.8% and 3.7% respectively. Histological transformation appeared after a median of 8 years. R-CHOP maintains safety and efficacy in patients with advanced FL over extended follow-up, making it a viable first-line option for patients with advanced-stage FL.
引用
- Watanabe T, Tobinai K, Wakabayashi M, et al. R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203. Br J Haematol. 2023. PMID: 37996986. doi:10.1111/bjh.19213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。